A Multicenter, Non-Randomized, Open-Label, Multiple-Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASKG712 Following Intravitreal Administration in Patients With Diabetic Macular Edema
Latest Information Update: 18 Jun 2026
At a glance
- Drugs VIS 101 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors AskGene Pharma
Most Recent Events
- 12 Jun 2026 Status changed from active, no longer recruiting to completed.
- 08 Sep 2025 Planned End Date changed from 1 Jul 2025 to 31 Dec 2025.
- 08 Sep 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.